Roivant Sciences (ROIV) Leerink Global Healthcare Conference 2026 summary

Business transformation and vision

• Entering a transformative period with multiple upcoming product launches and pivotal data readouts, signaling a shift toward commercial operations and profitability.

• Focused on delivering impactful therapeutics through creative partnerships, indication selection, and efficient R&D investment.

• Leadership team blends drug development expertise with investor perspectives, driving high ROI and unique portfolio decisions.

• Committed to maintaining a strong R&D foundation to support ongoing growth and compounding value.

Brepocitinib launch and market opportunity

• NDA for dermatomyositis accepted with priority review; launch expected by end of September.

• Targeting a U.S. patient population of about 40,000, with significant unmet need and high physician enthusiasm.

• Launch strategy emphasizes patient identification, referral center engagement, and robust patient support infrastructure.

• Oral administration and efficacy profile seen as major advantages over existing therapies like IVIG.

• Access strategy leverages proven orphan drug launch models, focusing on payer engagement and patient support hubs.

Brepocitinib safety and additional indications

• Safety profile consistent with JAK inhibitors, with manageable risks in high-need orphan populations.

• Physicians expected to prioritize efficacy over class safety concerns in severe indications.

• Phase II data in cutaneous sarcoidosis showed strong efficacy, with phase III to begin this year.

• Additional indications under consideration, with potential to expand the addressable market by 25–100%.